A decade af­ter its first ap­proval, FDA ex­pands weight loss pil­l's la­bel for use in ado­les­cents

The FDA late Mon­day signed off on a sup­ple­men­tal in­di­ca­tion for bank­rupt Vivus’ Qsymia (phen­ter­mine and top­i­ra­mate) for chron­ic weight man­age­ment in obese ado­les­cents aged …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER